Navigation Links
Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
Date:8/3/2009

EMERYVILLE, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that it will release financial results for the second quarter of fiscal year 2009 ended June 30, 2009 on Monday, August 10, 2009. The Company will conduct a conference call and web cast to review the financial results on Monday, August 10, 2009 at 5:00 p.m. ET.

Interested parties can access the call by dialing (800) 860-2442 or (412) 858-4600, or can listen via a live Internet web cast, which can be found at http://bionovo.com/investors/events. A replay of the call is available via web cast at http://bionovo.com/investors/events for 30 days or by playback at (877) 344-7549 or (412) 317-0088, conference code 432836, through August 13, 2009.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com. BNVI-F


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Announces Closing of Public Offering
2. International Milk Genomics & Human Health Symposium Speaker Program Announced
3. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores
6. Hoya Announces First Quarter Financial Results for FY2010
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
9. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
10. IIVS Announces Initiation by EPA of a Pilot Program to Evaluate Non-Animal Eye-Irritation Methods
11. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
(Date:12/5/2016)... The U.S. Biotechnology industry is ... of revenue and some $890 billion of total market ... biopharmaceuticals, and this figure is expected to exceed $220 ... these four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial genomics leader ... grant award has been made to Dr. Renato Polimanti of Yale University School ... the oral microbiome. Grant proposals have been vetted by the company’s scientific review ...
(Date:12/4/2016)... Mass. and CAMBRIDGE, Mass. ... Africa , Dec. 4, 2016 ... providing connected diagnostics software platforms for the developing ... making "Anywhere. Care.™" a reality with its portable ... have entered into a development and license agreement ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):